Similar Papers

Paper Title
Journal
Date
Author
BAFF and APRIL in Chronic Lymphocytic Leukemia: Clinico-Biological Correlates and Prognostic Significance.
Gerardo Ferrer ... Carol Moreno
Blood | VOL. 114
Gerardo Ferrer, et. al.Gerardo Ferrer ... Carol Moreno
20 Nov 2009
P26 Serum BAFF and APRIL as candidate biomarkers in systemic lupus erythematosus (SLE): a prospective follow-up study
Selma Sari ... Murat İnanç
Lupus Science & Medicine | VOL. 7
Selma Sari, et. al.Selma Sari ... Murat İnanç
01 Mar 2020
B cell\u2010activating factors in autoimmune pulmonary alveolar proteinosis
Masaki Hirose ... Yasushi Inoue
Orphanet Journal of Rare Diseases | VOL. 16
Masaki Hirose, et. al.Masaki Hirose ... Yasushi Inoue
02 Mar 2021
Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.
İlay Berke Menteşe ... Zübeyde Nur Özkurt
Indian Journal of Hematology and Blood Transfusion | VOL. 35
İlay Berke Menteşe, et. al.İlay Berke Menteşe ... Zübeyde Nur Özkurt
10 Oct 2018
View more papers

More From: The Journal of investigative dermatology

Paper Title
Journal
Date
Author
Knockout of IL-1R1 Reduced Inflammation and Improved Survival in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa.
Morgan Anderson-Crannage ... Yanling Liao
The Journal of investigative dermatology | VOL. -
Morgan Anderson-Crannage, et. al.Morgan Anderson-Crannage ... Yanling Liao
23 Jan 2025
Need for Trial Design Change in Epidermal Necrolysis (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis): Example of Cyclosporine.
Saskia Ingen-Housz-Oro ... Pierre Wolkenstein
The Journal of investigative dermatology | VOL. -
Saskia Ingen-Housz-Oro, et. al.Saskia Ingen-Housz-Oro ... Pierre Wolkenstein
22 Jan 2025
Subtype specific alterations in the skin microbiome of patients with cutaneous T-cell lymphoma.
Caroline Meyer Olesen ... Maria Rørbæk Kamstrup
The Journal of investigative dermatology | VOL. -
Caroline Meyer Olesen, et. al.Caroline Meyer Olesen ... Maria Rørbæk Kamstrup
21 Jan 2025
Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
Melinda J Gooderham ... Kim A Papp
The Journal of investigative dermatology | VOL. -
Melinda J Gooderham, et. al.Melinda J Gooderham ... Kim A Papp
21 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.